Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Global Antibiotic Research and Development Partnership

- PMLiVE

UK government’s AMR study highlights importance of appropriate antibiotic use

The UKHSA found that some bacteria are already becoming resistant to ceftazidime/avibactam

- PMLiVE

New genomic technique could improve antibiotic-resistant bacteria tracking in hospitals

The sequencing method is able to track the spread of multiple bacteria at the same time

- PMLiVE

WHO updates drug-resistant bacteria list to develop new treatments for AMR

The 2024 BPPL list includes 15 families of antibiotic-resistant bacteria

- PMLiVE

NICE recommends better targeting of antibiotics for suspected sepsis

It is hoped that the new guidance will reduce the risk of antibiotic resistance by ensuring antibiotics are targeted to those at the greatest risk

- PMLiVE

New antibiotic compound could potentially treat lethal hospital infections

Zosurabalpin successfully eliminated the multi-resistant A baumannii bacteria

- PMLiVE

MIT researchers identify new class of antibiotic candidates using AI

MRSA is a drug-resistant bacterium responsible for 10,000 deaths a year in the US

- PMLiVE

National surveillance data reveals increase in antibiotic resistant infections in England

The number of deaths due to severe antibiotic resistant infections also increased in 2022

- PMLiVE

Shionogi to acquire Qpex Biopharma for approximately $140m

The deal signifies a notable expansion to the Japanese drugmaker’s antimicrobial pipeline

- PMLiVE

Shionogi’s cefiderocol shows efficacy against difficult-to-treat bacterial infections

Antimicrobial resistance has been declared as one of the top ten threats to global health

- PMLiVE

European MPs call for urgent action against antimicrobial resistance

It is estimated that AMR could lead to as many as ten million deaths each year by 2050

- PMLiVE

Shionogi signs licence agreement with MPP for COVID-19 oral antiviral treatment

The agreement aims to increase access to ensitrelvir in low- and middle-income countries

- PMLiVE

Shionogi’s antiviral COVID-19 treatment meets phase 3 primary endpoint

Ensitrelvir reduced the time taken to resolve five key symptoms

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links